ResearchMoz

Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013

Global Markets Direct
Published Date » 2013-04-17
No. Of Pages » 138
   
 Global Markets Directs, 'Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects.  
   
 
 It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-Cell Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets...
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cutaneous T-Cell Lymphoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Cutaneous T-Cell Lymphoma 10
Cutaneous T-Cell Lymphoma Therapeutics under Development by Companies 12
Cutaneous T-Cell Lymphoma Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Pre-Clinical Stage Products 19
Comparative Analysis 19
Cutaneous T-Cell Lymphoma Therapeutics - Products under Development by Companies 20
Cutaneous T-Cell Lymphoma Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in Cutaneous T-Cell Lymphoma Therapeutics Development 23
Johnson & Johnson 23
Kyowa Hakko Kirin Co., Ltd. 24
Shionogi & Co., Ltd. 25
Seattle Genetics, Inc. 26
Emergent BioSolutions Inc. 27
Novartis AG 28
Eisai Co., Ltd. 29
Onyx Pharmaceuticals, Inc. 30
Mundipharma International Limited 31
Innate Pharma SA 32
Spectrum Pharmaceuticals, Inc. 33
Mondobiotech Holding AG 34
Yaupon Therapeutics, Inc. 35
ELORAC, Inc. 36
Cutaneous T-Cell Lymphoma - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 44
brentuximab vedotin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
panobinostat - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
carfilzomib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
everolimus - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
mogamulizumab - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
forodesine hydrochloride - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
mechlorethamine hydrochloride - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
pralatrexate - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
IPH-41 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
zanolimumab - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
belinostat + [bortezomib] - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
everolimus + panobinostat - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Therapeutic allogeneic lymphocytes program - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
quisinostat - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Rituximab + Carboplatin + Etoposide + Ifosfamide + Vorinostat - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
bexarotene - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
alefacept - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
naloxone hydrochloride - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
DasKloster-011201 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
DNA IL-12 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
[pralatrexate] + [bexarotene] - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
SHP-141 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Angeloxin - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
resiquimod - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Genetically Modified T Cells 1138 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
interferon gamma-1a - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Cutaneous T-Cell Lymphoma Therapeutics - Drug Profile Updates 95
Cutaneous T-Cell Lymphoma Therapeutics - Discontinued Products 125
Cutaneous T-Cell Lymphoma Therapeutics - Dormant Products 126
Cutaneous T-Cell Lymphoma - Product Development Milestones 128
Featured News & Press Releases 128
Nov 15, 2012: Elorac Obtains European Orphan Medical Product Designation For Naloxone Hydrochloride Dehydrate For Treatment Of Cutaneous T-cell Lymphoma 128
Nov 05, 2012: Seattle Genetics To Present Data On Adcetris And Antibody-Drug Conjugates At American Society Of Hematology Annual Meeting 128
Jul 09, 2012: OncoSec Initiates Phase II Clinical Program In Cutaneous T-Cell Lymphoma And Doses First Patient 130
Jun 05, 2012: Ceptaris Receives Complete Response Letter From FDA For Mechlorethamine Gel 131
Jun 05, 2012: Ceptaris Receives Complete Response Letter From FDA For Mechlorethamine Gel 131
May 10, 2012: Seattle Genetics Presents Interim Results From Phase II Trial Of ADCETRIS At Society For Investigative Dermatology Annual Meeting 131
Jan 26, 2012: Seattle Genetics Announces Data From ADCETRIS In Cutaneous T-Cell Lymphoma And Peripheral T-Cell Lymphoma 132
Jan 25, 2012: Study Shows Leukemia Drug Kills Cancerous T-cells While Sparing Normal Immunity 134
Jan 18, 2012: Ceptaris Receives Orphan Drug Designation From EMA For Mechlorethamine Gel 134
Oct 04, 2011: FDA Accepts Filing Of NDA For Yaupongel's Gel Formulation Of Mechlorethamine Hydrochloride 135

Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 137
Disclaimer 137

List of Tables


Number of Products Under Development for Cutaneous T-Cell Lymphoma, H1 2013 10
Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Development by Companies, H1 2013 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2013 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Development by Companies, H1 2013 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2013 22
Johnson & Johnson, H1 2013 23
Kyowa Hakko Kirin Co., Ltd., H1 2013 24
Shionogi & Co., Ltd., H1 2013 25
Seattle Genetics, Inc., H1 2013 26
Emergent BioSolutions Inc., H1 2013 27
Novartis AG, H1 2013 28
Eisai Co., Ltd., H1 2013 29
Onyx Pharmaceuticals, Inc., H1 2013 30
Mundipharma International Limited, H1 2013 31
Innate Pharma SA, H1 2013 32
Spectrum Pharmaceuticals, Inc., H1 2013 33
Mondobiotech Holding AG, H1 2013 34
Yaupon Therapeutics, Inc., H1 2013 35
ELORAC, Inc., H1 2013 36
Assessment by Monotherapy Products, H1 2013 37
Assessment by Combination Products, H1 2013 38
Assessment by Stage and Route of Administration, H1 2013 40
Assessment by Stage and Molecule Type, H1 2013 43
Cutaneous T-Cell Lymphoma Therapeutics - Drug Profile Updates 95
Cutaneous T-Cell Lymphoma Therapeutics - Discontinued Products 125
Cutaneous T-Cell Lymphoma Therapeutics - Dormant Products 126
Cutaneous T-Cell Lymphoma Therapeutics - Dormant Products (Contd..1) 127

List of Figures


Number of Products under Development for Cutaneous T-Cell Lymphoma, H1 2013 10
Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 15
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Pre-Clinical Stage Products, H1 2013 19
Assessment by Monotherapy Products, H1 2013 37
Assessment by Combination Products, H1 2013 38
Assessment by Route of Administration, H1 2013 39
Assessment by Stage and Route of Administration, H1 2013 40
Assessment by Molecule Type, H1 2013 41
Assessment by Stage and Molecule Type, H1 2013 42

Upcoming Reports:

MTBE Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Methyl tertiary butyl ether (MTBE) is a colorless, volatile, flammable liquid majorly used as fuel component. MTBE is manufactured by catalytic reaction of isobutylene with methanol. MTBE is used as an octane buster in engines. It is also used as oxygenate to increase oxygen in gasoline. MTBE offers good blending properties and reduces the content of formaldehyde and benzene in gasoline. Additionally, it replaces lead compounds enhancing the anti-knocking properties of the fuel. It is also used as a laboratory reagent to extract compounds. It is also used as solvent to dissolve gallstones....
Insulation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Insulation refers to a process wherein a non-conducting material is used to isolate something from its surroundings, and sustain its normal state of being. It can be used for different purposes like sound, heat, and electricity insulation. However, the insulation market is heavily influenced by the high-growth building-insulation market. This market can be classified into residential, non-residential, and industrial insulation. Insulators are useful for controlling the energy efficiency of the house, or in an industrial setting and also in reducing the carbon footprint. Insulators can...
Smart And Interactive Textiles Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Smart textiles are fabrics that have electronic and digital components embedded in them. There is a seamless integration of textiles with electronic elements such as sensors, actuators and micro-controllers. Smart textiles can be classified into two categories viz., passive smart textiles and active smart textiles. Passive smart textiles include textiles which provide additional features irrespective of the change in environment. Active smart textiles are textiles which adapt functionality to environment automatically. Smart textiles can be used in a large variety of applications such as...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
Samsung Records Poorest Profits in Q3 2014
Oct 29, 2014  
In the quarter ending September 2014, Samsung Electronics Co. Ltd registered the smallest earnings ever in two years. The drop in earnings can be easily attributed to heavy competition from new Chinese devices and the Apple phones. The net income stood at US$4 billion for the South Korea-based company. Apple has been Samsung’s strongest contender ever since the latter entered the...